1. Home
  2. Bills
  3. H.R. 5547

H.R. 5547 · 118th Congress · 2023–2024

Maintaining Investments in New Innovation Act

H.R. 5547 in the 118th Congress (2023–2024) was introduced on Sep 18, 2023, sponsored by Wiley Nickel with 28 co-sponsors.

During the 118th Congress (2023–2024), Joe Biden was president, and Republicans held the House majority and Democrats the Senate majority.

Status
Introduced
Introduced
Sep 18, 2023
Co-sponsors
28
Policy area
Health

What it does

Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026.

Summary by the nonpartisan Congressional Research Service.

Sponsor

Wiley Nickel (D-NC). Co-sponsors: 5 Democrats, 23 Republicans.

Where it stands

  • IntroducedSep 18, 2023
  • Passed the House—
  • Passed the Senate—
  • Sent to the President—
  • Became law—

Latest action: Referred to the Subcommittee on Health. (Dec 17, 2024)

More bills from Wiley Nickel in the 118th Congress

Other Health bills in the 118th Congress

Committees

More

From GovInfo bill records, Congressional Research Service summaries, Voteview roll calls and lobbying reports.

Cite or embed this page

Capitol Receipts, “H.R. 5547 (118th Congress): Maintaining Investments in New…,” https://www.capitolreceipts.com/bill/118-hr-5547/maintaining-investments-in-new-innovation-act (accessed 2026-10-17).

Open the interactive version ›